Learn more about patient advocacy and how to influence!
Are you between 18 to 35, living in Europe and affected by a neurological disorder? Then you can participate in
Read more.
Accelerated evaluation of drug
The European Medicines Agency has acknowledged the huntingtin lowering drug, RG6042 (previously known as IONIS-HTTRx), as a possible therapy that
Read more.
EFNA Survey: need for increased awareness
A newly published survey conducted by EFNA, shows that young Europeans with neurological conditions lives with a fear of isolation
Read more.
Huntington’s Disease Youth Organization needs you!
HDYO is looking to hold a review meeting on the future direction of the Young Adult Working Group of EHDN
Read more.
News from EHDN
Read about the Registery journey from the very beginning to the more recent successor study Enroll-HD. Cristina Ferreira gives you
Read more.
An exciting new therapy
Read more.
A letter from Roche
Roche Pharmaceuticals is currently working on their Huntingtin Lowering drug, RG6042 (formerly known as IONIS-HTTRx). In the letter Patient Partnership
Read more.
You are invited to Vienna!
In September the European Huntington Association is arranging their Business Meeting in Vienna. This year the association wants to encourage
Read more.
May is Huntington Disease Awareness Month
Read more.